UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000004227 |
|---|---|
| Receipt number | R000005081 |
| Scientific Title | Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small cell lung cancer |
| Date of disclosure of the study information | 2010/09/17 |
| Last modified on | 2011/03/17 13:08:02 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small cell lung cancer
Acronym
Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small cell lung cancer
Scientific Title
Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small cell lung cancer
Scientific Title:Acronym
Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small cell lung cancer
Region
| Japan |
Condition
Condition
advanced non-small cell lung cancer
Classification by specialty
| Pneumology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To evaluate the efficacy and safety of erlotinib monotherapy as third-line chemotherapy
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Phase II
Assessment
Primary outcomes
overall response rate
Key secondary outcomes
overall survival time, safety,progression-free survival
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Patients started to receive erlotinib (150 mg, p.o.) daily after experiencing recurrence or disease progression after second-line treatment. Treatment was continued until disease progression or unacceptable toxicity occurred. Doses were adjusted to 100 mg per day according to the toxicity.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Pathologically confirmed inoperable stage IIIB or stage IV NSCLC
ECOG performance status of 0-2
naive for EGFR tyrosine kinase inhibitors
two prior systemic chemotherapy regimens, one of which was a platinum-containing regimen
Adequate function of the bone marrow, liver and kidney
Key exclusion criteria
user of EGFR tyrosine kinase inhibitors
severe complications or active interstitial lung disease
Target sample size
30
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Kingo Chida |
Organization
Hamamatsu University School of Medicine
Division name
Respiratory medicine
Zip code
Address
1-20-1 Handayama, Hamamatsu, Japan
TEL
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name |
Organization
Hamamatsu University School of Medicine
Division name
Respiratory medicien
Zip code
Address
TEL
Homepage URL
Sponsor or person
Institute
Hamamatsu University School of Medicine
Institute
Department
Personal name
Funding Source
Organization
Hamamatsu University School of Medicine
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
浜松医科大学附属病院
Other administrative information
Date of disclosure of the study information
| 2010 | Year | 09 | Month | 17 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2008 | Year | 06 | Month | 01 | Day |
Date of IRB
Anticipated trial start date
| 2009 | Year | 01 | Month | 01 | Day |
Last follow-up date
| 2010 | Year | 01 | Month | 01 | Day |
Date of closure to data entry
| 2010 | Year | 02 | Month | 01 | Day |
Date trial data considered complete
| 2010 | Year | 02 | Month | 01 | Day |
Date analysis concluded
| 2010 | Year | 12 | Month | 01 | Day |
Other
Other related information
Management information
Registered date
| 2010 | Year | 09 | Month | 17 | Day |
Last modified on
| 2011 | Year | 03 | Month | 17 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005081
